Liver cancer is the sixth most common cancer in the world, with close to 800,000 patients worldwide diagnosed with the disease annually. Current methods of diagnosis include blood tests, ultrasound imaging, CT scans, and MRI scans. MRI offers a highly detailed visualization of the tumor and often helps determine if the tumor is benign or malignant. However, contrast agents used for MRI imaging have significant disadvantages such as low specificity, rapid excretion by the liver, and uncontrolled retention time in the body. This often leads to a late stage diagnosis, drastically reducing the options available to treat the disease. Now, a new protein-based MRI contrast agent has been developed by researchers from Emory University, University of Georgia, and University of Virginia, and their work was recently published in Proceedings of National Academy of Sciences.
Hey, check out all the engineering jobs. Post your resume today!